3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 1
3
Phase 2
2
Status
Recruiting
6
Active not recruiting
3
Terminated
2
Not yet recruiting
2
Completed
2
Sponsor Class
NETWORK
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Recurrence
1
Multiple Myeloma
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Cyclophosphamide
739
Cisplatin
687
Gemcitabine
641
Bevacizumab
615
Carboplatin
604
Paclitaxel
600
Docetaxel
565
Radiotherapy
536
Fluorouracil
405
Oxaliplatin
387
Rituximab
369
Doxorubicin
360
Capecitabine
342
Filgrastim
333
Etoposide
328
Dexamethasone
312
Irinotecan
309
pembrolizumab
279
Leucovorin
274
Cetuximab
267
Cytarabine
242
Erlotinib Hydrochloride
231
Prednisone
227
Nivolumab
227
Trastuzumab
225
Bortezomib
221
Vincristine
220
Methotrexate
207
Pemetrexed
199
fludarabine phosphate
195
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Completed
×
belantamab mafodotin
×
Clear all
NCT05064358
2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2
Completed
177 enrolled
37 charts
NCT04617925
2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2
Completed
35 enrolled